MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

Molecular Pharmacology Fast Forward
First published on April 3, 2007; DOI: 10.1124/mol.107.035113

0026-895X/07/7201-1-7$20.00
Mol Pharmacol 72:1-7, 2007

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.107.035113v1
72/1/1    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lazo, J. S.
Right arrow Articles by Dingledine, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lazo, J. S.
Right arrow Articles by Dingledine, R.
Minireview

Building a Pharmacological Lexicon: Small Molecule Discovery in Academia

John S. Lazo, Linda S. Brady, and Ray Dingledine

Department of Pharmacology, Pittsburgh Molecular Library Screening Center, University of Pittsburgh Drug Discovery Institute, University of Pittsburgh, Pittsburgh, Pennsylvania (J.S.L.); Molecular Screening Centers Network, Division of Neuroscience and Basic Behavioral Science, National Institute of Mental Health, Bethesda, Maryland (L.S.B.); and Department of Pharmacology, Emory Chemical-Biology Discovery Center, Emory University, Atlanta, Georgia (R.D.)

Small molecules are powerful pharmacological tools to dissect biological events. There is now considerable interest in expanding efforts to identify and use small molecules targeting proteins encoded in the genomes of humans and pathogenic organisms. Integration of the principles of molecular pharmacology with contemporary high-throughput and high-content screening technologies is essential for the success of these discovery activities. We present some of the challenges and opportunities provided by the Molecular Library Screening Centers Network (MLSCN), which is a National Institutes of Health Roadmap Initiative.

Received February 11, 2007; accepted March 29, 2007

Address correspondence to: John S. Lazo, Department of Pharmacology, Pittsburgh Molecular Library Screening Center, University of Pittsburgh, Biomedical Science Tower 3, Suite 10040, Pittsburgh, PA 15261-0001. E-mail: lazo{at}pitt.edu; Raymond Dingledine, Department of Pharmacology, Emory Chemical-Biology Center, 1510 Clifton Rd., Emory University, Atlanta, GA 30322. E-mail: rdingledine{at}pharm.emory.edu




This article has been cited by other articles:


Home page
 Mol. Pharmacol.Home page
F. Madoux, X. Li, P. Chase, G. Zastrow, M. D. Cameron, J. J. Conkright, P. R. Griffin, S. Thacher, and P. Hodder
Potent, Selective and Cell Penetrant Inhibitors of SF-1 by Functional Ultra-High-Throughput Screening
Mol. Pharmacol., June 1, 2008; 73(6): 1776 - 1784.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
N. Kumar, R. Afeyan, H.-D. Kim, and D. A. Lauffenburger
Multipathway Model Enables Prediction of Kinase Inhibitor Cross-Talk Effects on Migration of Her2-Overexpressing Mammary Epithelial Cells
Mol. Pharmacol., June 1, 2008; 73(6): 1668 - 1678.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics